NeuroNova/Genentech (Sweden) Drug Class: Peptide Mechanism/Technology: NeuroNova has two drug candidates nearing clinical development for Parkinson’s disease and ALS. NN0029 is a novel drug candidate for the treatment of amyotrophic lateral sclerosis (ALS) that has demonstrated in preclinical in vivo studies the ability to slow disease progression and increase life span. The pharmaceutical formulation contains vascular endothelial growth factor (VEGF) protein, which will be delivered by ICV infusion. Primary Indication: Parkinson's Disease, ALS Stage: Phase I/II
